1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Tatva Chintan Pharma Chem Limited

Tatva Chintan Pharma Chem Limited

1,572.10
INR
-87.50
(-5.27%)
21.97EPS
54.17P/E
27.84BMarket Cap
Jan 21Next Earn
Tatva Chintan Pharma Chem Limited
BSE:TATVA
(Bombay Stock Exchange)

Recent

price

1,572.10

P/E

ratio

54.17

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
100.78
128.28
133.93
200.61
189.89
170.6
162.41
214.01
237.74
Revenue per Share
10.23
18.81
23.58
44.59
20.52
13.26
2.44
17.98
21.97
Basic EPS, GAAP
-1.21
-11.38
-0.67
-32.06
-79.1
-13.31
-22.02
-35.18
- -
Free Cash Flow per Basic Share
- -
- -
1.81
- -
2
2.04
2
1
- -
Dividend per Share
35.96
53.1
74.88
213.44
232.25
315.1
315.84
334.2
- -
Book Value per Share
35.9
53.04
74.83
213.3
232.04
313.41
313.32
331.28
- -
Tangible Book Value per Share
20
20
22
21
22
23
23
23
23
Basic Weighted Avg Shares
2,024
2,577
2,969
4,313
4,209
3,905
3,799
5,006
5,560
Sales/Revenue/Turnover
15.83
20.81
20.22
23.37
13.95
11.3
1.82
11.87
12.53
Operating Margin (%)
40
48
67
82
96
256
277
368
384
Depreciation Expense
205
378
523
959
455
304
57
421
514
Net Income, GAAP
25.01
20.61
13.9
7.92
- -
30.33
24.62
26.23
25.55
Effective Tax Rate (%)
10.15
14.66
17.61
22.23
10.81
7.77
1.5
8.4
9.24
Profit Margin (%)
417
450
662
2,644
736
2,182
1,692
1,364
- -
Working Capital
315
387
268
131
42
6
- -
50
- -
LT Debt
797
1,177
1,660
4,731
5,148
7,371
7,388
7,818
- -
Total Equity
- -
23.3
22.22
21.78
- -
4.25
0.67
5.21
- -
Return on Invested Capital (%)
- -
22.32
23.97
23.52
- -
4.82
0.84
5.24
- -
Return on Capital (%)
- -
38.29
36.85
30.01
9.21
4.85
0.77
5.53
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,154
- -
LT Borrowings
- -
50
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
31,268
24,583
27,839

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,495
- -
Cash, Cash Equivalents & STI
- -
61
- -
Accounts Receivable, Net
- -
1,190
- -
Inventories
- -
1,961
- -
Total Current Liabilities
- -
2,131
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,154
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
48.62%
5.81%
Free Cash Flow
- -
954.08%
59.78%
Net Income, GAAP
- -
110.51%
636.11%
Sales/Revenue/Turnover
- -
12.95%
31.78%
Total Cash Common Dividend
- -
- -
-50%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,055
835
859
1,079
3,799
2026
1,169
1,235
1,313
1,341
5,006
2027
1,671
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.23
-0.29
0.06
0.44
2.44
2026
2.84
4.24
6.49
4.41
17.98
2027
6.83
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Tatva Chintan Pharma Chem Limited manufactures specialty chemicals, focusing on phase transfer catalysts (PTCs), structure directing agents (SDAs), electrolyte salts and solutions for batteries, pharmaceutical and agrochemical intermediates, other specialty chemicals, and brominated flame retardants; it serves industries including automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances. Founded in 1996 and headquartered in Vadodara, Gujarat, India, the company operates manufacturing facilities in Ankleshwar and Dahej SEZ in Bharuch, Gujarat, with an R&D center in Vadodara and subsidiaries Tatva Chintan Europe B.V. and Tatva Chintan USA Inc., supporting geographic operations across the US, Europe, Japan, and India. Recent developments include investor Mukul Mahavir Agrawal acquiring a 1.28% stake in mid-2025, the commencement of commercial production for two new photochlorination and agrochemical products in late FY25 alongside continuous flow chemistry advancements for monoglyme, expansion into earth metal extraction chemicals and electrolyte salts for super-capacitor, zinc, and sodium batteries targeting inflection from CY25, and participation in the ICSCE 2025 agrochemical conference in Dubai to showcase intermediates and PTCs.